Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, +37

New England Journal of Medicine

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington, +4

Journal of Clinical Oncology

Surgical OncologyOncologic ImagingCancer ManagementPathologyLugano Classification +20

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam, +21

New England Journal of Medicine

Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma

Lorena Appio, Carlo Landoni, Maria La Targia, +6

Chemotherapy

Cell TherapyImmunologyImmunotherapyCancer ChemotherapyTranslational Medicine +15

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng, +25

Journal of Clinical Oncology

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, +13

Blood Advances

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma

N. George Mikhaeel, Martin Hutchings, Paul Fields, +2

Annals of Oncology

Lymphoid NeoplasiaOverall SurvivalMedicinePathologyHigh-grade Non-hodgkin Lymphoma +6

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun, +21

Blood Advances

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Caron A. Jacobson, Bradley D. Hunter, Robert Redd, +24

Journal of Clinical Oncology

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Matthew J. Frank, Nasheed Hossain, Ali Bukhari, +15

Journal of Clinical Oncology